Bendamustine + Pomalidomide + Dex in R/R Multiple Myeloma
Status:
Active, not recruiting
Trial end date:
2023-01-01
Target enrollment:
Participant gender:
Summary
This study is designed as a phase I-II, open label, dose finding study.
Study treatment will be as follows, in 28 day cycles:
- Pomalidomide: once daily orally (PO) dosing on days 1-21, every 28 days
- Bendamustine: once intravenously (IV) dosing on day 1, every 28 days
- Dexamethasone: weekly PO or IV dosing on days 1, 8, 15, and 22.
After completing 6 cycles of treatment, dexamethasone may be decreased to 20mg per
investigator discretion. After completing 12 cycles of treatment, patients will proceed to
the maintenance phase of the study. Patients will receive Pomalidomide on day 1-21, every 28
days and dexamethasone on days 1, 8, 15, and 22 every 28 days until time of progression.